📬 Melanoma Intelligence Digest — Week 2026-W29
Neoadjuvant immunotherapy for resectable melanoma delivers trial-comparable outcomes in a nationwide Swedish cohort, while real-world data confirm chemotherapy after immunotherapy remains poorly active in advanced disease.
⚡ TL;DR
📄 Publications
- Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort. — Nationwide cohort of 279 consecutive patients with resectable stage III-IV cutaneous melanoma treated with neoadjuvant ICI in Sweden
🐦 Twitter / 🦋 Bluesky
- GEM1801 real-world data show chemotherapy after immunotherapy remains poorly active in advanced melanoma — In 92 patients treated with chemotherapy after prior immunotherapy, ORR was 12%, mPFS 3.5 months and mOS 6.1 months
- Meta-analysis of neoadjuvant ICI before surgery in resectable stage III/IV melanoma reports high pathological response and low surgical failure — Systematic review and meta-analysis of 20 studies, n=1,384, reported pCR 33%, MPR 46%, overall pathological response 59%
Full details below ↓
📄 What's Being Published
Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort. — Nelson Axel et al., J Natl Cancer Inst
This nationwide, population-based cohort study included 279 consecutive patients with resectable stage III-IV cutaneous melanoma treated with neoadjuvant ICI in Sweden; 94% received PD-1 inhibitor monotherapy and 92% underwent surgery as planned. Major pathological response occurred in 43%, including 37% with complete response. After a median follow-up of 20 months, estimated 24-month EFS was 69%, DMFS 75%, and OS 87%; among 119 patients achieving major pathological response, withholding adjuvant therapy was associated with recurrence.
Clinical bottom line: Neoadjuvant PD-1 inhibitor therapy for resectable stage III-IV melanoma reproduces randomized-trial outcomes in routine Swedish practice, but stopping adjuvant therapy after major pathological response was linked to recurrence.
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
GEM1801 real-world data show chemotherapy after immunotherapy remains poorly active in advanced melanoma
In 92 patients treated with chemotherapy after prior immunotherapy, ORR was 12%, mPFS 3.5 months, and mOS 6.1 months; outcomes remained poor regardless of the chemotherapy regimen used. Whether chemotherapy retains any meaningful role after immunotherapy failure in advanced melanoma remains unresolved, with these figures offering little basis for optimism across regimens.
Discussed by: @OncoAlert, @JournalCancer
Meta-analysis of neoadjuvant ICI before surgery in resectable stage III/IV melanoma reports high pathological response and low surgical failure
A systematic review and meta-analysis of 20 studies (n=1,384) reported pCR 33%, MPR 46%, and overall pathological response 59%, with failure or delay to surgery at 9% and major surgical complications at 8%. Real-world outcomes were also published for neoadjuvant nivolumab and ipilimumab in clinical stage III melanoma from a community cancer center, sharpening debate over how reliably these pathological response rates translate from trials to community and nationwide practice.
Discussed by: @OncoAlert, @SurgOncInsight
🔥 Top Ranked Tweets
Dr. Patrick Hwu @PatrickHwuMD
🧬 #ScienceSaturday
❓ What if cancer treatment decisions could be guided not only by the tumor cells themselves, but by the ecosystem around them?
➡️ A new study in @Nature introduces a machine-learning approach to study the tumor microenvironment, or the “neighborhood” around tumor cells made up of immune cells, blood vessel cells, fibroblasts and other supporting cells.
➡️ Researchers analyzed more than 10 million single-cell and spatial transcriptomic profiles across multiple cancer types to understand not only which cells are present in tumors, but where they are located and how they interact.
➡️ They identified nine recurring “spatial ecotypes,” or tumor neighborhoods, each with distinct biology and location patterns. Some were found near the tumor core, others at the tumor edge or surrounding tissue.
➡️ Importantly, some of these tumor neighborhoods were linked to patient outcomes and response to immune checkpoint inhibitors, a type of immunotherapy that helps the immune system recognize and attack cancer.
➡️ The most exciting part: the team showed that these spatial patterns could also be detected using cell-free DNA from blood samples, offering a potential non-invasive way to better understand the tumor microenvironment.
➡️ In patients with melanoma, these blood-based signals were strongly associated with response to immunotherapy, suggesting this approach could one day help guide treatment decisions.
💡 The takeaway: tumors are more than just cancer cells. Their surrounding ecosystem plays a major role in how cancer grows, hides and responds to treatment. This study points to a future where liquid biopsies may help us read that ecosystem in real time, bringing us closer to more personalized cancer care.
@AaronNewmanLab @Stanford @czbiohub @MayoClinic @Yale @rondell_graham @YaleGenetics @YaleCancer @SmilowCancer @StanfordCancer @Columbia @columbiacancer @columbiamed @MedicalCollege @Oslounivsykehus @WashUMedicine @UniOslo @WilmotCancer
Read more: https://t.co/OOwjAAFtzm
🔖 57 ❤️ 78 🔁 25 👁 7,083
OncoAlert @OncoAlert
RT @NiuSanford: Important survivorship data for anal SCC. Definitive chemoRT achieves cure in most, but w substantial functional cost. In PRO study, 62% of pts w/o stoma had major LARS.
De-escalation RCTs (DECREASE fully accrued, PLATO-ACT4 w early results) critical for improving QOL @OncoAlert https://t.co/bVGzwCJpjs
🔖 14 ❤️ 50 🔁 19 👁 3,169
OncoAlert @OncoAlert
RT @MarioBalsaMD: 📄 Surgical feasibility and outcomes following neoadjuvant ICI before surgery in resectable stage III/IV melanoma (Systematic review & meta-analysis, 20 studies, n=1,384)
https://t.co/bt4k1TaH03
🎯 pCR 33% | MPR 46% | Overall pathological response 59%
🔴 Failure/delay to surgery: 9%
⚠️ Major surgical complications: 8%
💥 Lower recurrence risk vs adjuvant approaches
@OncoAlert
@OncoReporte @myESMO @_SEOM
🔖 3 ❤️ 9 🔁 7 👁 808
PeerView @PeerView
Melanoma immunotherapy continues to evolve. Hear Geoffrey T. Gibney, MD, and Meredith McKean, MD, MPH (@MeredithMcKean), discuss the latest evidence across resectable and metastatic disease: https://t.co/sI37NNZyQ2
#ASCO26 #Melanoma #CME #MedEd
🔖 1 ❤️ 4 🔁 2 👁 157
Surgical Oncology Insight @SurgOncInsight
Published: Neoadjuvant nivolumab and ipilimumab for clinical stage III #Melanoma : Real world outcomes from a community cancer center
https://t.co/XQUiHs35Gn
@FlavioRochaMD
@DrMikeCavnar
@SKMaithel
@HalletJulie
@JulietOkoroh
@TheNotoriousHPB
@AradhyaNigamMD
@SocSurgOnc https://t.co/vlB3OEZTmP
🔖 0 ❤️ 3 🔁 2 👁 470
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.